PMID- 17972902
OWN - NLM
STAT- MEDLINE
DCOM- 20080128
LR  - 20211020
IS  - 1469-221X (Print)
IS  - 1469-3178 (Electronic)
IS  - 1469-221X (Linking)
VI  - 8
IP  - 11
DP  - 2007 Nov
TI  - Non-classical major histocompatibility complex proteins as determinants of tumour 
      immunosurveillance.
PG  - 1024-30
AB  - Tumours develop in vertebrate organisms endowed with immune systems that are 
      potentially able to eradicate them. Nevertheless, our ever-increasing 
      understanding of the complex interactions between lymphocytes and tumour cells 
      fuels the long-standing hope of developing efficient immunotherapies against 
      cancer. This review focuses on a versatile family of proteins, the major 
      histocompatibility complex class Ib, which has been recently implicated in both 
      the establishment of anti-tumour immune responses and in tumour immune response 
      evasion. We focus on a subset of class Ib proteins, human leukocyte antigen 
      (HLA)-G, Qa-2, CD1d and NKG2D ligands, which bind to either stimulatory or 
      inhibitory receptors expressed on T, natural killer (NK) and NKT lymphocytes, and 
      thereby modulate their anti-tumour activity.
FAU - Gomes, Anita Q
AU  - Gomes AQ
AD  - Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 
      Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal.
FAU - Correia, Daniel V
AU  - Correia DV
FAU - Silva-Santos, Bruno
AU  - Silva-Santos B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - EMBO Rep
JT  - EMBO reports
JID - 100963049
RN  - 0 (Antigens, CD1)
RN  - 0 (Antigens, CD1d)
RN  - 0 (CD1D protein, human)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (KLRK1 protein, human)
RN  - 0 (Lipids)
RN  - 0 (MHC Ib Qa-2 antigen)
RN  - 0 (NK Cell Lectin-Like Receptor Subfamily K)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Natural Killer Cell)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Antigens, CD1/immunology
MH  - Antigens, CD1d
MH  - HLA Antigens/*immunology
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Lipids/immunology
MH  - *Major Histocompatibility Complex
MH  - *Monitoring, Immunologic
MH  - NK Cell Lectin-Like Receptor Subfamily K
MH  - Neoplasms/*immunology
MH  - Peptides/immunology
MH  - Receptors, Immunologic/immunology
MH  - Receptors, Natural Killer Cell
MH  - T-Lymphocytes/immunology
PMC - PMC2247375
EDAT- 2007/11/02 09:00
MHDA- 2008/01/29 09:00
PMCR- 2008/11/01
CRDT- 2007/11/02 09:00
PHST- 2007/01/30 00:00 [received]
PHST- 2007/09/13 00:00 [accepted]
PHST- 2007/11/02 09:00 [pubmed]
PHST- 2008/01/29 09:00 [medline]
PHST- 2007/11/02 09:00 [entrez]
PHST- 2008/11/01 00:00 [pmc-release]
AID - 7401090 [pii]
AID - 10.1038/sj.embor.7401090 [doi]
PST - ppublish
SO  - EMBO Rep. 2007 Nov;8(11):1024-30. doi: 10.1038/sj.embor.7401090.